Madam Chair, the context we're working in, of course, is the pandemic. It impacted timelines for the development of the guidelines by the Patented Medicine Prices Review Board, which were developed through consultation.
Those were finalized in the middle part of the fall, and the government took a decision to delay their coming into force to ensure that the guidelines were in place and understood, to support the implementation of the PMPRB regulations.